EcoDrugPlus

Somatostatin Receptor 5

Ensembl ID : ENSGEVG00005013056
Gene Symbol: SSTR5
1 Cross references
257 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sphingosine Kinase 2

Ensembl ID : ENSGEVG00005005002
Gene Symbol: SPHK2
3 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSGEVG00005011691
Gene Symbol: S1PR1
3 Cross references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Spleen Associated Tyrosine Kinase

Ensembl ID : ENSGEVG00005003598
Gene Symbol: SYK
3 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Steroid 5 Alpha-Reductase 2

Ensembl ID : ENSGEVG00005009403
Gene Symbol: SRD5A2
3 Cross references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Sterol O-Acyltransferase 1

Ensembl ID : ENSGEVG00005009452
Gene Symbol: SOAT1
3 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Synuclein Alpha

Ensembl ID : ENSGEVG00005010556
Gene Symbol: SNCA
3 Cross references
189 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tachykinin Receptor 1

Ensembl ID : ENSGEVG00005005891
Gene Symbol: TACR1
1 Cross references
271 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tachykinin Receptor 3

Ensembl ID : ENSGEVG00005006387
Gene Symbol: TACR3
1 Cross references
258 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Telomerase Reverse Transcriptase

Ensembl ID : ENSGEVG00005002124
Gene Symbol: TERT
1 Cross references
188 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Thromboxane A Synthase 1

Ensembl ID : ENSGEVG00005012172
Gene Symbol: TBXAS1
3 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Thromboxane A2 Receptor

Ensembl ID : ENSGEVG00005014923
Gene Symbol: TBXA2R
3 Cross references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).